Management to host conference call and webcast at 4:30 pm ET on that dayBoca Raton, Florida, March 24, 2026 (GLOBE NEWSWIRE) -- INmune Bio ...

Plenary Presentation Highlights How Aligning Inflammatory Biomarker Enrichment with Mechanism of Action Offers a Blueprint for Success in ...

As we reflect on 2025, I want to thank you for your continued support of INmune Bio. This past year marked an important period of execution, discipline, and focus as we advanced our mission to develop ...

Released top-line data from the MINDFuL phase 2 trial in 208 patients with MCI and early Alzheimer’s. The trial missed its primary cognitive endpoints in the 200 modified mITT patients enrolled, ...

The company’s reliance on future clinical trial results introduces significant uncertainty regarding the potential success of its drug candidates, highlighting risks that may deter investors. The ...

INmune Bio Inc. (NASDAQ:INMB) stock is trading lower on Monday, with a session volume of 23.2 million, compared to the average volume of 1.45 million, as per data from Benzinga Pro. The company ...

Represents First Ever Natural Killer Immunotherapy trial in Metastatic Castration-Resistant Prostate Cancer Webinar at 11AM ET on Friday, May 12. BOCA RATON, Fla., May 08, 2023 (GLOBE NEWSWIRE) -- ...

Boca Raton, Florida, Dec. 08, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness the ...

The Company received a cash refund of approximately $2.8M USD pursuant to an Australian Research and Development Tax Incentive. Boca Raton, Florida, Nov. 15, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. ...

Top-line results from the MINDFuL phase 2 trial in Alzheimer’s expected in the second half of June. Presented baseline demographics and disease profiles of participants in the MINDFuL phase II study ...